Circulating plasma lncRNAs as novel markers of <i>EGFR</i> mutation status and monitors of epidermal growth factor receptor‐tyrosine kinase inhibitor therapy

Abstract

This study shows that lncRNAs can be used not only as potential biomarkers for predicting the mutation status of EGFR and the efficacy of EGFR-TKI, but also for monitoring the efficacy of EGFR-TKI.